No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that highlevel results from an interim analysis of its Phase III I CAN trial showed Ultomiris had met its primary endpoint, delivering a statistically significant and meaningful reduction in proteinuria in adults with IgA nephropathy at risk of disease progression.
AstraZeneca said the main efficacy measure - changes in estimated glomerular filtration rates - would be assessed at week 106.
IgA nephropathy is a rare inflammatory kidney condition that can lead to chronic and ultimately endstage disease. The FTSE 100-listed company highlighted that more than 560,000 people were diagnosed with the condition across the US, EU5 and Japan - with over 60% eligible for treatment.
AstraZeneca also stated it would seek accelerated approval in key markets and that it will present the trial's results at a forthcoming medical meeting.
As of 0845 BST, AstraZeneca shares were down 1.15% at 14,780p.
Reporting by Iain Gilbert at Sharecast.com
See latest RNS at Investegate
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.